

SCIENTIFIC REPORTS

OPEN

Author Correction: Combination of KIR2DS4 and *Fc γ R1a* polymorphisms predicts the response to cetuximab in *KRAS* mutant metastatic colorectal cancer

A. Borrero-Palacios¹, A. Cebrián¹, M. T. Gómez del Pulgar¹, R. García-Carbonero², P. García-Alfonso³, E. Aranda⁴, E. Elez⁵, R. López-López⁶, A. Cervantes⁷, M. Valladares⁸, C. Nadal⁹, J. M. Viéitez¹⁰, C. Guillén-Ponce¹¹, J. Rodríguez¹², I. Hernández¹³, J. L. García¹⁴, R. Vega-Bravo¹⁵, A. Puime-Otin¹⁵, J. Martínez-Useros¹, L. Del Puerto-Nevado¹, R. Rincón¹, M. Rodríguez-Remírez¹, F. Rojo¹⁵ & J. García-Foncillas¹

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-019-39291-2>, published online 22 February 2019

The original version of this Article contained an error in the spelling of the author P. Garcia-Alfonso, which was incorrectly given as P. Garcia. This error has now been corrected in the PDF and HTML versions of this Article.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

¹Translational Oncology Division, Oncohealth Institute, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain. ²Medical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain. ³Medical Oncology Department, Hospital Gral. Univ. Gregorio Marañón, Madrid, Spain. ⁴Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain. ⁵Medical Oncology Department, Hospital Vall d'Hebrón, Barcelona, Spain. ⁶Medical Oncology Department, Complejo Hospitalario Universitario Santiago de Compostela, Galicia, Spain. ⁷Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain. ⁸Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Galicia, Spain. ⁹Medical Oncology Department, Hospital Clínic Provincial de Barcelona, Barcelona, Spain. ¹⁰Medical Oncology Department, Hospital Universitario Central de Asturias, Asturias, Spain. ¹¹Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. ¹²Medical Oncology Department, Clínica Universitaria de Navarra, Navarra, Spain. ¹³Medical Oncology Department, Complejo Hospitalario de Navarra, Navarra, Spain. ¹⁴Oncology, Medical Unit, Merck S.L, an affiliate of Merck KGaA, Darmstadt, Germany. ¹⁵Anatomopathology Department, Hospital Universitario "Fundación Jimenez Diaz", Madrid, Spain. A. Borrero-Palacios and A. Cebrián contributed equally. Correspondence and requests for materials should be addressed to A.C. (email: aranca.cebrian@oncohealth.eu) or J.G.-F. (email: jesus.garciafoncillas@oncohealth.eu)